News

A fingerprint of exhaled breath
Enlarge image

ResearchSwitzerland

A fingerprint of exhaled breath

04.04.2013 - Researchers from ETH Zurich have shown that the individual fingerprint of exhaled breath can be used for diagnostic purposes.

The team headed by Renato Zenobi reports in the journal PLoS that real-time analysis of the metabolic pattern found in exhaled breath can help to diagnose and monitor diseases. Using mass spectrometry (SESI-MS), the ETH researchers found that the chemical "fingerprint" of exhaled breath of 11 volunteers showed an individual core pattern and remained stable over time. According to the researchers, linking up that metabolic ID with genetic susceptibility to diseases can help diagnosing manifestation of diseases more individually. Shortly before, US researchers had published results of a MS-based study for diagnosis of heart failure

"We did find some small variations during the day, but overall the individual pattern stays sufficiently constant to be useful for medical purposes," says Pablo Martinez-Lozano Sinues, senior scientist in Zenobi's research group. To carry out these measurements, Zenobi and his colleagues modified commercial mass spectrometers by adding a breath sampling inlet line that delivers exhaled breath from a mouth piece directly into the ion source of the instrument. Mass spectra showing peaks of roughly 100 compounds in breath can be easily and rapidly obtained. 

The researchers are working to recognise characteristic patterns of lung diseases with the same technology. Although the potential usefulness of analysing breath for medical diagnosis has been known, it is rarely done in academic medicine. "This might be due to the fact that existing methods for breath analysis are either rather slow, or are limited to a small number of compounds that they can detect," says Sinues. Compared to analysis of blood or urine, a significant advantage of the ETH researchers’ approach is that the breath fingerprint is available within seconds. Another benefit is that exhaling into the ion source of a mass spectrometer is completely non-invasive. They researchers see huge potential to use the method as a tool for early detection of certain diseases in risk populations and in therapy monitoring.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/a-fingerprint-of-exhaled-breath.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%

FLOP

  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 25.04.2015